Highlights

  • Invion received an R&D Tax Incentive cash refund of approximately AU$502,675 for FY26 eligible research activities conducted in Australia.
  • The refund is non-dilutive, supplementing other Capital sources without requiring the issuance of new Equity to shareholders.
  • Invion's lead programme, INV043 on the Photosoft™ platform, is advancing toward planned Phase II trials in skin cancer and anogenital cancer.
  • Two complementary financing arrangements are designed to cover up to approximately 85% of anticipated future clinical trial costs, with the Peter MacCallum Cancer Centre co-sponsoring the anogenital trial.

Invion Limited (ASX:IVX), a clinical-stage life sciences company developing its next-generation photodynamic therapy (NGPDT) platform under the Photosoft™ brand, has confirmed receipt of a Research and Development Tax Incentive cash refund of approximately AU$502,675 for the FY26 financial year. This refund was delivered under the Australian Government's R&D Tax Incentive programme, a mechanism designed to encourage sustained Investment in innovation by providing eligible companies with a tax offset or cash refund based on a proportion of qualifying R&D expenditure incurred domestically. The timing of the refund — as the company approaches a pivotal period of clinical activity — adds to its available capital without requiring a share Placement or other dilutive financing action. For early-stage life sciences companies with limited or no commercial revenue, maintaining a mix of non-dilutive funding sources alongside equity capital is a key aspect of financial stewardship, and the R&D Tax Incentive represents an annually recurring contribution to this objective given the nature of the company's ongoing research activities.

The Photosoft™ Platform and Its Clinical Rationale

Photosoft™ is Invion's proprietary platform for next-generation photodynamic therapy — a treatment approach in which non-toxic photosensitising compounds are administered and then activated by targeted light exposure to generate a localised cell-killing effect within tumour tissue. The NGPDT mechanism is designed to selectively destroy cancer cells while stimulating an immune response against tumour antigens, a combination that may contribute to both direct tumour elimination and longer-term disease control. The company presents the approach as less invasive than surgical Options and characterised by a more acceptable side effect profile than many conventional cancer treatments, with the potential for complete tumour regression and durable remission in responsive indications. Invion holds a global exclusive licence to the Photosoft™ technology for cancer, ophthalmic and certain non-cancer indications, providing intellectual property protection across its targeted development programme. The lead compound, INV043, is the primary clinical candidate being evaluated across multiple cancer types.

Planned Phase II Trials and Co-Sponsorship

The most immediate clinical priorities for Invion are planned Phase II studies in skin cancer and in anogenital cancer, the latter of which is being co-sponsored by the Peter MacCallum Cancer Centre in Melbourne. Co-sponsorship by an institution with the stature of Peter MacCallum — Australia's dedicated national cancer centre and one of the world's recognised leaders in oncology research — confers significant scientific credibility on the anogenital programme and may assist in regulatory navigation, site activation and patient recruitment. Prior to announcing the R&D Tax Incentive refund, Invion disclosed two complementary financing structures designed to collectively cover a substantial portion of the future clinical trial costs, reducing the company's capital exposure to trial expenditure and extending its operational runway. The company characterises the R&D Tax Incentive as a component of a broader funding strategy that also includes these trial-specific arrangements and positions the clinical programme for execution without excessive recourse to equity markets.

Antimicrobial and Ophthalmic Applications of Photosoft™

While oncology is Invion's primary development focus, the Photosoft™ platform has demonstrated potential in applications beyond cancer. Preclinical work has shown broad-spectrum antimicrobial activity against bacteria, fungi and viruses — a capability that may eventually support development of treatments for topical or systemic infections, particularly in settings where antimicrobial resistance limits conventional treatment options. Ophthalmic applications represent another potential avenue for the platform, with photodynamic therapy having an established clinical history in certain eye conditions. These adjacent application areas are not currently the company's commercial priority, but they represent optionality within the Photosoft™ licence that may become relevant as the primary oncology programmes generate data and the platform's clinical Utility is better characterised. The breadth of potential applications underscores the value of the global exclusive licence the company holds.

Key Insights

The R&D Tax Incentive refund is a modest but constructive capital event that reflects the sustained domestic research activity underlying Invion's clinical pipeline. As a recurring mechanism tied to eligible Australian R&D expenditure, it represents a predictable contribution to the company's non-dilutive funding mix in future years, provided research activities continue at comparable intensity. The more consequential near-term milestones for investors are the progression of the Phase II skin cancer and anogenital trials, where clinical data will ultimately determine the commercial and partnering potential of the Photosoft™ platform. The Peter MacCallum co-sponsorship of the anogenital trial is a reputational and practical asset that may accelerate the pathway from trial initiation to meaningful readout data.